
NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Managing the Statin-Intolerant Patient: Low-Dose/Low-Frequency Treatment Regimens
Statin clinical trials suggest an incidence of adverse muscular events of ~ 1.5 – 3%, but the true incidence of statin intolerance (SI) is likely…
Understanding Statin use in America and Gaps in Education – USAGE Survey
Statins play a critical role in reducing the risk of heart disease. Not only are the benefits greatly appreciated by both physicians and patients, the…
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients
The importance of non–HDL cholesterol reporting in lipid management
The importance of non–HDL cholesterol reporting in lipid management
NLA Endorses Newly Published 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk
Jacksonville, Florida – (August 25, 2022) – The American College of Cardiology (ACC) announced the release of the 2022 ACC Expert Consensus Decision Pathway on…
Amgen Makes Repatha® Available Through AmgenNow, A Direct-to-patient Program in the US
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly…